Beijing's SL Pharma and Canada's PnuVax Form Vaccine, Antibody JV
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Beijing's SL Pharmaceutical announced it will invest CAD $20 million to form a joint venture in Ontario, Canada with Canadian partner PnuVax Incorporated.
You may also be interested in...
Finance Watch: J&J Notes JLabs Incubators' Success Stories To Date
Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.
Are China’s Vaccines Ready For The World?
With WHO approval in hand, China’s vaccine industry looks to take the next step into global markets.
Vaccines Shakeup Continues In China: NT Pharma Backs Away From GSK
SHANGHAI - China's largest vaccine distributor China NT Pharma Group announced Aug. 17 it will not renew its master distribution contract with its largest customer GlaxoSmithKline PLC, in part, it appears, due to burdens created by the new China Pharmacopeia that was issued at the end of 2010